SZodixStudyAcademic Library
ShelvesOpen access
Study · an open academic library·Metadata from OpenAlex (CC0)·Shelves·OpenAlex metadata, de-duplicated
New drugs cost US$2.6 billion to develop
0 references·4 citing·12 second hop
New drugs cost US$2.6 billion to develop (2014)New drugs cost US$2.6 billion to developThe pharmaceutical productivity gap – Incremental decline in R&D efficiency despite transient improvements (2024)The pharmaceutical productivi…A modelling framework for improved design and decision-making in drug development (2019)A modelling framework for imp…Bridging the translational gap: collaborative drug development and dispelling the stigma of commercialization (2015)Bridging the translational ga…Antibody-drug conjugates: Intellectual property considerations (2015)Antibody-drug conjugates: Int…Capitalism, Socialism and Democracy (1997)Capitalism, Socialism and Democracy (2010)Academic engagement and commercialisation: A review of the literature on university–industry relations (2012)Leveraging Research Failures to Accelerate Drug Discovery and Development (2019)Responsible use of negative research outcomes—accelerating the discovery and development of new antibiotics (2021)The cost of biopharmaceutical R&D: is biotech different? (2007)Patent trend and competitive analysis of cancer immunotherapy in the United States (2017)Trends in the intellectual property (IP) landscape of drug delivery systems (2020)How to improve R&D productivity: the pharmaceutical industry's grand challenge (2010)Clinical development success rates for investigational drugs (2014)Innovation in the pharmaceutical industry: New estimates of R&D costs (2016)The price of innovation: new estimates of drug development costs (2003)
this work references cited by second hop

References

No references inside the corpus for this window.

Cited by

  • 2024The pharmaceutical productivity gap – Incremental decline in R&D efficiency despite transient improvements51 cited
  • 2015Bridging the translational gap: collaborative drug development and dispelling the stigma of commercialization30 cited
  • 2015Antibody-drug conjugates: Intellectual property considerations18 cited
  • 2019A modelling framework for improved design and decision-making in drug development18 cited

Only edges whose both ends are imported exist here. Widen the year window, or show the whole map. Back to the work